Natera, Inc. (NASDAQ:NTRA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 7.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,090,480 shares of the medical research company’s stock after purchasing an additional 143,825 shares during the period. Geode Capital Management LLC owned about 1.58% of Natera worth $265,747,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Itau Unibanco Holding S.A. purchased a new stake in Natera during the 2nd quarter worth approximately $28,000. Quarry LP grew its stake in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares in the last quarter. Covestor Ltd raised its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. Finally, True Wealth Design LLC purchased a new position in Natera in the third quarter valued at $57,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Leerink Partners boosted their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Piper Sandler upped their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday. Finally, Craig Hallum boosted their target price on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $152.67.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares in the company, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the transaction, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. The trade was a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,987 shares of company stock worth $21,895,591 over the last 90 days. 7.60% of the stock is currently owned by insiders.

Natera Trading Up 0.1 %

NASDAQ NTRA opened at $166.55 on Friday. The firm’s fifty day moving average is $144.02 and its two-hundred day moving average is $124.56. Natera, Inc. has a one year low of $57.22 and a one year high of $175.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm has a market cap of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the firm posted ($0.95) EPS. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. Analysts expect that Natera, Inc. will post -1.61 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.